Biotech Values

[DewDiligence]

VRUS/Roche: Hmm…notably absent from the section of yesterday’s VRUS’ PR that enumerates 2010 clinical news (#msg-53137438) is any mention of a phase-2b trial of RG7128 + SoC in genotype-2/3 patients. This is curious insofar as VRUS’ PR from Feb 2010 (#msg-46762882) said:

Roche is planning to initiate a Phase 2b study of RG7128 in combination with pegylated interferon and ribavirin in patients with HCV genotypes 2 and 3 later in 2010.

A reasonable inference is that this phase-2b trial is no longer planned. If this is in fact the case, the decision by Roche not to run such a study makes perfect sense, IMO.